Scheffler S, Kuckelkorn U, Egerer K, Dörner T, Reiter K, Soza A, Burmester G-R, Feist E
Department of Medicine/Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany.
Rheumatology (Oxford). 2008 May;47(5):622-6. doi: 10.1093/rheumatology/ken042. Epub 2008 Mar 27.
Autoantibodies against the 20S-proteasome display a broad diversity with a remarkably low frequency of individual cross-reactivity against the different subunits of the proteasome. Although their pathogenic and diagnostic significance remains obscure, an involvement in the clearance of circulating proteasomes as well as an interaction with the activity of the proteolytic complex was assumed in previous studies.
To investigate the anti-proteasome response in more detail and to disclose reactivities against former neglected subunits, two-dimensional electrophoresis followed by immunoblotting was used. As a novel antigen source, the immunosubunits LMP2 (beta1i) and LMP7 (beta5i) were expressed as recombinant proteins and employed in ELISA.
The subunits Iota (alpha1) and Zeta (alpha5) of the outer rings as well as the catalytic subunit Delta (beta1) and all three immunosubunits [MECL-1 (beta2i), LMP2 (beta1i) and LMP7 (beta5i)] of the inner rings of the proteasome were identified as autoantigens for the first time. Using a panel of anti-proteasome antibody-positive sera of patients with SLE, autoimmune myositis (PM/DM) and primary Sjögren's syndrome (pSS), an autoimmune response was documented against LMP2 (beta1i) and LMP7 (beta5i) in all three patient groups in ELISA.
The frequent autoimmune response against LMP2 (beta1i) and LMP7 (beta5i) might indicate a role of inflammatory processes in the primary induction of the anti-proteasomal immune reaction, while the diversity of the humoral response against the proteasome system supports the assumption of a specific antigen-driven process leading to these extended autoimmune reactivities.
针对20S蛋白酶体的自身抗体表现出广泛的多样性,针对蛋白酶体不同亚基的个体交叉反应频率极低。尽管它们的致病和诊断意义仍不明确,但先前的研究推测其参与循环蛋白酶体的清除以及与蛋白水解复合物活性的相互作用。
为了更详细地研究抗蛋白酶体反应并揭示针对先前被忽视亚基的反应性,采用了二维电泳后免疫印迹法。作为一种新型抗原来源,免疫亚基LMP2(β1i)和LMP7(β5i)被表达为重组蛋白并用于酶联免疫吸附测定(ELISA)。
首次将蛋白酶体外环亚基Iota(α1)和Zeta(α5)以及内环的催化亚基Delta(β1)和所有三个免疫亚基[MECL-1(β2i)、LMP2(β1i)和LMP7(β5i)]鉴定为自身抗原。使用一组系统性红斑狼疮(SLE)、自身免疫性肌炎(PM/DM)和原发性干燥综合征(pSS)患者的抗蛋白酶体抗体阳性血清,ELISA检测记录了所有三个患者组中针对LMP2(β1i)和LMP7(β5i)的自身免疫反应。
针对LMP2(β1i)和LMP7(β5i)频繁的自身免疫反应可能表明炎症过程在抗蛋白酶体免疫反应的初始诱导中起作用,而针对蛋白酶体系统的体液反应的多样性支持了一种特定抗原驱动过程导致这些扩展的自身免疫反应性的假设。